Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Increased depression, diabetes and diabetic complications in Graves' disease patients in Asia.

Chen HH, Yeh SY, Lin CL, Chang SN, Kao CH.

QJM. 2014 Sep;107(9):727-33. doi: 10.1093/qjmed/hcu069.

PMID:
24664351
2.

Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.

Le Moli R, Muscia V, Tumminia A, Frittitta L, Buscema M, Palermo F, Sciacca L, Squatrito S, Vigneri R.

Nutr Metab Cardiovasc Dis. 2015 May;25(5):452-7. doi: 10.1016/j.numecd.2015.01.003.

PMID:
25746910
3.

Cancer risk in patients with Graves' disease: a nationwide cohort study.

Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, Cheng YH, Kao CH.

Thyroid. 2013 Jul;23(7):879-84. doi: 10.1089/thy.2012.0568.

5.

Both interleukin-23A polymorphism and serum interlukin-23 expression are associated with Graves' disease risk.

Jia H, Tao F, Liu C, Guo T, Zhu W, Wang S, Cui B, Ning G.

Cell Immunol. 2015 Mar;294(1):39-43. doi: 10.1016/j.cellimm.2015.01.015.

PMID:
25670394
6.

Significantly increased risk of cardiovascular disease among patients with gallstone disease: a population-based cohort study.

Olaiya MT, Chiou HY, Jeng JS, Lien LM, Hsieh FI.

PLoS One. 2013 Oct 3;8(10):e76448. doi: 10.1371/journal.pone.0076448.

7.

[Evaluation of the medical treatment of Graves' disease (GD)].

Peixoto MC, Coeli CM, Vaisman M.

Arq Bras Endocrinol Metabol. 2005 Jun;49(3):410-9. Portuguese.

8.

Genetic association between IL-17F gene polymorphisms and the pathogenesis of Graves' Disease in the Han Chinese population.

Guo T, Huo Y, Zhu W, Xu F, Liu C, Liu N, Cao M, Cui B, Ning G.

Gene. 2013 Jan 10;512(2):300-4. doi: 10.1016/j.gene.2012.10.021.

PMID:
23111159
9.

Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine.

Tsymbaliuk I, Unukovych D, Shvets N, Dinets A.

PLoS One. 2015 Mar 24;10(3):e0122388. doi: 10.1371/journal.pone.0122388.

10.

The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal.

Tanrikulu S, Erbil Y, Ademoglu E, Işsever H, Barbaros U, Kutlutürk F, Ozarmagan S, Tezelman S.

Endocrine. 2006 Dec;30(3):377-81.

PMID:
17526951
11.

HbA1c in the diagnosis of diabetes and abnormal glucose tolerance in patients with Graves' hyperthyroidism.

Yang L, Shen X, Yan S, Yuan X, Lu J, Wei W.

Diabetes Res Clin Pract. 2013 Jul;101(1):28-34. doi: 10.1016/j.diabres.2013.04.008.

PMID:
23684448
12.
13.

Association of TLR7 and TSHR copy number variation with Graves' disease and Graves' ophthalmopathy in Chinese population in Taiwan.

Liao WL, Wan L, Wang TY, Chen CC, Tse SS, Lu CH, Tsai FJ.

BMC Ophthalmol. 2014 Feb 11;14:15. doi: 10.1186/1471-2415-14-15.

14.

Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.

Clin Endocrinol (Oxf). 2006 Feb;64(2):189-95.

PMID:
16430719
15.

Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis.

Marinò M, Barbesino G, Pinchera A, Manetti L, Ricciardi R, Rossi B, Muratorio A, Braverman LE, Mariotti S, Chiovato L.

Thyroid. 2000 Sep;10(9):799-802.

PMID:
11041457
16.

Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study.

Lai HC, Lin CC, Cheng KS, Kao JT, Chou JW, Peng CY, Lai SW, Chen PC, Sung FC.

Gastroenterology. 2014 Jan;146(1):129-37.e1. doi: 10.1053/j.gastro.2013.09.058.

PMID:
24095786
17.

A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis.

Chou CH, Lin MC, Peng CL, Wu YC, Sung FC, Kao CH, Liu SH.

Scand J Rheumatol. 2014;43(2):132-6. doi: 10.3109/03009742.2013.822097.

PMID:
24134400
18.

Mental health status and factors that influence the course of Graves' disease and antithyroid treatments.

Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH.

Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):524-8. doi: 10.1055/s-0032-1323807.

PMID:
23070829
19.

Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.

Esfahani AF, Kakhki VR, Fallahi B, Eftekhari M, Beiki D, Saghari M, Takavar A.

Hell J Nucl Med. 2005 Sep-Dec;8(3):158-61.

PMID:
16390021
20.

Characterization of the anaemia associated with Graves' disease.

Gianoukakis AG, Leigh MJ, Richards P, Christenson PD, Hakimian A, Fu P, Niihara Y, Smith TJ.

Clin Endocrinol (Oxf). 2009 May;70(5):781-7. doi: 10.1111/j.1365-2265.2008.03382.x.

Items per page

Supplemental Content

Support Center